The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin
Joseph A. Jakubowski(Indiana Biosciences Research Institute), Andrew L. Frelinger(University of Nottingham), Alan D. Michelson(Harvard University), Matthew D. Linden(University of Massachusetts Chan Medical School), Kenneth J. Winters(Eli Lilly (United States)), Mark I. Furman, Atsuhiro Sugidachi(Daiichi Sankyo (United Kingdom)), Marc R. Barnard, Marsha L. Fox(Pediatrics and Genetics)
Cited by 48
Related Papers
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials
|The Lancet|2009|723
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents
|Journal of the American College of Cardiology|2012|617
Platelet Glycoprotein Ibα Is a Counterreceptor for the Leukocyte Integrin Mac-1 (Cd11b/Cd18)
|The Journal of Experimental Medicine|2000|582